<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170349</url>
  </required_header>
  <id_info>
    <org_study_id>2016-05</org_study_id>
    <nct_id>NCT03170349</nct_id>
  </id_info>
  <brief_title>The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study</brief_title>
  <acronym>CLASP</acronym>
  <official_title>The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, performance and clinical outcomes of the
      Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the safety, performance and clinical outcomes of the
      Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System. This is a multi-center,
      multi-national, prospective, single arm, safety, performance and clinical outcomes study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of major adverse events (MAE) defined as cardiovascular mortality, stroke, myocardial infarction, new need for renal replacement therapy, severe bleeding and re-intervention for study device related complications at 30 days.</measure>
    <time_frame>The primary endpoint will be assessed at 30 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation reduction</measure>
    <time_frame>30 days, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days , 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent heart failure hospitalization</measure>
    <time_frame>30 days , 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Six Minute Walk Test (6MWT) distance</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Edwards PASCAL Transcatheter Mitral Valve Repair System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Valve Repair</intervention_name>
    <description>Minimal Invasive Transcatheter Mitral Valve Repair</description>
    <arm_group_label>Edwards PASCAL Transcatheter Mitral Valve Repair System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated IRB/ethics committee approved study consent form prior to study
             related procedures

          -  Eighteen (18) years of age or older

          -  New York Heart Association (NYHA) Functional Class II-IVa heart failure despite
             optimal medical therapy

          -  Candidacy for surgical mitral valve repair or replacement determined by Heart Team
             evaluation

          -  Clinically significant mitral regurgitation (moderate-to-severe or severe mitral
             regurgitation) confirmed by transesophageal echocardiography (TEE) and transthoracic
             echocardiography (TTE).

          -  The primary regurgitant jet is non-commissural. If a secondary jet exists, it must be
             considered clinically insignificant.

          -  Mitral valve area (MVA) ≥ 4.0 cm² as measured by planimetry. If MVA by planimetry is
             not measurable, pressure half-time measurement is acceptable.

        Exclusion Criteria:

          -  Patient in whom a TEE is contraindicated or screening TEE is unsuccessful

          -  Leaflet anatomy which may preclude PASCAL device implantation, proper device
             positioning on the leaflets, or sufficient reduction in mitral regurgitation.

          -  Mitral valve area (MVA) &lt; 4.0 cm² as measured by planimetry (If MVA by planimetry is
             not measurable, PHT measurement is acceptable)

          -  Echocardiographic evidence of intracardiac mass, thrombus, or vegetation

          -  Physical evidence of right sided congestive heart failure and echocardiographic
             evidence of severe right ventricular dysfunction

          -  Concurrent medical condition with a life expectancy of less than 12 months in the
             judgment of the Investigator

          -  Patient is currently participating or has participated in another investigational drug
             or device clinical study where the primary study endpoint was not reached at time of
             enrollment

          -  Patient is under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jill Trekell</last_name>
    <phone>+1 949-250-2672</phone>
    <email>Jill_Trekell@edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mane Arabyan</last_name>
      <phone>310-248-8515</phone>
      <email>mane.arabyan@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Salazar</last_name>
      <phone>(310) 967-4375</phone>
      <email>kelly.salazar@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Saibal Kar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Trento, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danny Ramzy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siddharth Singh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale Siefert, RN</last_name>
      <phone>847-570-2368</phone>
      <email>dseifert@northshore.org</email>
    </contact>
    <contact_backup>
      <last_name>Ujala Bokhary, MBBS, CCRP</last_name>
      <phone>847-570-2089</phone>
      <email>Ubokhary@northshore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ted Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Aberle, RN</last_name>
      <phone>704-355-4794</phone>
      <email>Sally.Aberle@carolinashealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Susan McClain, RN</last_name>
      <phone>704-355-4794</phone>
      <email>Susan.Mcclain@carolinashealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany ZIngler</last_name>
      <phone>469-814-4737</phone>
      <email>Brittany.Zingler@bswhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Necole Kell</last_name>
      <phone>469-814-4871</phone>
    </contact_backup>
    <investigator>
      <last_name>Robert L Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Bailes, RN, CCRC</last_name>
      <phone>434-982-1058</phone>
      <email>Lgs2m@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Morris</last_name>
      <phone>434-982-1058</phone>
      <email>JLM6UW@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>D. Scott Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro North Hospital &amp; Health Service, The Prince Charles Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Chermside</state>
        <zip>QLD 4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney Local Health District, Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Ng, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+61 2 9515 7110</phone>
    </contact_backup>
    <investigator>
      <last_name>Martin Ng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, Providence Health Care Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Webb, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+1 604 806-8804</phone>
    </contact_backup>
    <investigator>
      <last_name>John Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gideon Cohen, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+1 416-480-6077</phone>
    </contact_backup>
    <investigator>
      <last_name>Gideon Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Michael Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B-1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Fam, MD</last_name>
      <phone>416-864-3086</phone>
    </contact>
    <investigator>
      <last_name>Neil Fam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Rafaelle Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azeem Latib, MD</last_name>
      <phone>+39 22 64 37 331</phone>
      <email>Latib.azeem@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

